Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck

Oncologist

Volumn 18, Issue 10, 2013, Pages 1108-1117

  Kostakoglu, Lale ^a   Fardanesh, Reza ^a   Posner, Marshall ^a   Som, Peter ^a   Rao, Srikar ^a   Park, Eunice ^a   Doucette, John ^a   Stein, Evan ^a   Gupta, Vishal ^a   Misiukiewicz, Krzysztof ^a   Genden, Eric ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Head and neck cancer; PET CT; Surveillance and survival

Indexed keywords

ADULT; AGED; ARTICLE; BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DISTANT METASTASIS; ENDOSCOPY; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HEALTH INSURANCE; HUMAN; HUMAN TISSUE; LARYNGECTOMY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; CANCER STAGING; DIAGNOSTIC USE; EARLY DIAGNOSIS; HEAD AND NECK NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SQUAMOUS CELL; PATHOLOGY; PROCEDURES; RADIOGRAPHY; SURVIVAL; VERY ELDERLY;

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; AGED, 80 AND OVER; EARLY DIAGNOSIS; ENDOSCOPY; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL ANALYSIS;

EID: 84886075178     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0068     Document Type: Article

References (61)

1. Vokes EE, Weichselbaum RR, Lippman SM et al. Head and neck cancer. N Engl J Med 1993;328:184-194.
2. Scher RL, Esclamado RM. Organ and function preservation: The role of surgery as the optimal primary modality or as salvage after chemoradiation failure. Semin Radiat Oncol 2009;19:17-23.
3. Vermorken J, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;11: 1116-1127.
4. Machiels JP, Subramanian S, Ruzsa A et al. Zalutumumabplus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomized phase 3 trial. Lancet Oncol 2011;12:333-343.
5. Machiels JPH, Henry S, Zanetta S et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28:21-28.
6. Lee JC, Kim JS, Lee JH et al. F-18 FDG-PET as a routine surveillance tool for the detection of recur-rent head and neck squamous cell carcinoma. Oral Oncol 2007;43:686-692.
7. Ryan WR, Fee WE Jr. Le QT et al. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005;115:645-650.
8. Kim G, Kim YS, Han EJ et al. FDG-PET/CT as prognostic factorandsurveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer. Radiat Oncol J 2011;29:243-251.
9. Schoder H, Yeung HW, GonenMet al. Head and neck cancer: Clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004;231:65-72.
10. Branstetter BF 4th, Blodgett TM, Zimmer LA et al. Head and neck malignancy: Is PET/CT more accurate than PET or CT alone? Radiology 2005;235: 580-586.
11. Fakhry N, Lussato D, Jacob T et al. Comparison between PET and PET/CT in recurrent head and neck cancer and clinical implications. Eur Arch Otorhinolaryngol 2007;264:531-538.
12. ChenAY, Vilaseca I, HudginsPAet al. PET-CTvs. contrast-enhanced CT: What is the role for each after chemoradiation for advanced oropharyngeal cancer? Head Neck 2006;28:487-495.
13. Inohara H, Enomoto K, Tomiyama Y et al. The role of CT and (18)F-FDG PET in managing the neck in node-positive headandneck cancer afterchemoradiotherapy. Acta Otolaryngol 2008;7:1-7.
14. National Comprehensive Cancer Network. Clinical practice guidelines in Oncology Head and Neck Cancers V. 2 2013. Available at http://www. nccn.org/professionals/physician_gls/pdf/headand-neck.pdf. Accessed August 2, 2013.
15. O'Meara WP, Thiringer JK, Johnstone PA. Follow-up of head and neck cancer patients post-radiotherapy. Radiother Oncol 2003;66:323-326.
16. Hawass NE. Comparing the sensitivities and specificities of two diagnostic procedures performed on the same group of patients. Br J Radiol 1997;70:360-366.
17. Begg AC. Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol 2012;22:108-118.
18. Norton L. Conceptual and practical implications of breast tissue geometry: Toward a more effective, less toxic therapy. The Oncologist 2005;10: 370-381.
19. Ho AS, Tsao GJ, Chen FW et al. Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer 2013;119: 1349-1356.
20. McCollum AD, Burrell SC, Haddad RI et al. Positron emission tomography with 18-F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck 2004;26:890-896.
21. LoweVJ, BoydJH, DunphyFRet al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18:651-658.
22. Beswick DM, Gooding WE, Johnson JT et al. Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/ computed tomography monitoring. Laryngoscope 2012;122:1512-1517.
23. Yao M, Smith RB, Hoffman HT et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucosepositron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys 2009; 74:9-14.
24. Wang YF, Liu RS, Chu PY et al. Positron emission tomography in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy. Head Neck 2009;31:442-451.
25. Kissun D, Magennis P, LoweDet al. Timing and presentation of recurrent oral and oropharyngeal squamous cell carcinoma and awareness in the outpatient clinic. Br J Oral Maxillofac Surg 2006;44: 371-376.
26. Pearlmann NW. Treatment outcome in recurrent head and neck cancer. Arch Surg 1979;114:39-42.
27. Cooney TR, Poulsen MG. Is routine follow-up useful after combined-modality therapy for advanced head and neck cancer? Arch Otolaryngol Head Neck Surg 1999;125:379-382.
28. Schwartz DL, Barker Jr J, Chansky K et al. Postradiotherapy surveillance practice for head and neck squamous cell carcinoma-too much for too little? Head Neck 2003;25:990-999.
29. de Visscher AV, Manni JJ. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity. Does it make sense? Arch Otolaryngol Head Neck Surg 1994;120:934-939.
30. Zhang I, Branstetter BF 4th, Beswick DM et al. The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2011;137:1106-1111.
31. Hermans R. Posttreatment imaging in head and neck cancer. Eur J Radiol 2008;66:501-511.
32. Misiti A, Macori F, Caimietal M. Computerized tomography in the evaluation of the larynx after surgical treatment and irradiation Radiol Med 1997;94:600-606.
33. Pameijer FA, Hermans R, Mancuso AA et al. Pre-and post-radiotherapy computed tomography in laryngeal cancer: Imaging-based prediction of local failure Int J Radiat Oncol Biol Phys 1999;45:359-366.
34. Mukherji SK, Mancuso AA, Kotzuretal IM. Radiologic appearance of the irradiated larynx. Part II. Primary site response Radiology 1994:193;149-154.
35. Ong SC, Schöder H, Lee NY et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008;49: 532-540.
36. Gupta T, Master Z, Kannan S et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011;38:2083-2095.
37. Boysen M, Lövdal O, Tausjö J et al. The value of follow-up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer 1992;28: 426-430.
38. Agra IM, Ferlito A, TakesRPet al. Diagnosisand treatment of recurrent laryngeal cancer following initial nonsurgical therapy. Head Neck 2012;34: 727-735.
39. Ensley J, Ahmed K, Kish J et al. Salvage of patients with advanced squamous cell cancers of the head and neck (SCCHN) following induction chemotherapy failure using radiation and concurrent cisplatin (CACP). In: Salmon S, ed. Adjuvant Therapy of Cancer: Proceedings of the International Conference on the Adjuvant Therapy of Cancer. VI. Philadelphia, PA: W.B. Saunders Company, 1990:92-100.
40. Specenier P, Vermorken JB. Biologic therapy in headandneckcancer:Aroadwith hurdles. ISRNOncol 2012:163752, 2012.
41. DaSilva SD, HierM, MlynarekAet al. Recurrent oral cancer: Current and emerging therapeutic approaches. Front Pharmacol 2012;3:149.
42. Goodwin W. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: When do the ends justify the means? Laryngoscope 2000;110 (3 Pt 2 Suppl 93:1-18.
43. Brizel DM, Prosnitz RG, Hunter S et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-andneck cancer. Int J Radiat Oncol Biol Phys 2004;58: 1418-1423.
44. Argiris A, StensonKM, BrocksteinBEet al. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck 2004;26:447-455.
45. Lavertu P, Adelstein DJ, Saxton JP et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck 1997;19:559-566.
46. McHamSA, Adelstein DJ, Rybicki LA et al. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3squamous cell head and neck cancer? Head Neck 2003;25:791-798.
47. Terhaard CH, Bongers V, van Rijk PP et al. F-18-fluoro-deoxyglucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 2001;23:933-941.
48. PorcedduSV, JarmolowskiE, Hicks RJ et al. Utility of positron emission tomography for the detection of disease in residual necknodesafter (chemo)-radiotherapy in head and neck cancer. Head Neck 2005;27:175-181.
49. Porceddu SV, Pryor DI, Burmeister E et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011;33: 1675-1682.
50. Castaldi P, Rufini V, Bussu F et al. Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol 2012;103:63-68.
51. Sheriff JM, Ogunremi B, Colley S et al. The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy. Br J Radiol 2012;85:e1120-1126.
52. Moeller BJ, Rana V, Cannon BA et al. Prospective risk-adjusted [18F] fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol 2009;27:2509-2515.
53. Rabalais A, Walvekar RR, Johnson JT et al. A cost-effectiveness analysis of positron emission tomography-computed tomography surveillance versus up-front neck dissection for management of the neck for N2 disease after chemoradiotherapy. Laryngoscope 2012;122:311-314.
54. Nakamura S, Toriihara A, Okochi K et al. Optimal timing of post-treatment [18F]fluorodeoxyglucose-PET/CT for patients with head and neck malignancy. Nucl Med Commun 2013;34:162-167.
55. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210-222.
56. Abgral R, Querellou S, PotardGet al. Does 18FFDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:24-29.
57. Abgral R, Le Roux PY, Keromnes N et al. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2012;39: 1839-1847.
58. Gourin CG, Williams HT, SeaboltWNet al. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope 2006;116:705-710.
59. Argiris A, Brockstein BE, Haraf DJ et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004;10:1956-1962.
60. Wong RJ, Lin DT, Schoder H et al. Diagnostic and prognostic value of [(18)F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002;20:4199-4208.
61. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.